Semaglutide News and Research

Latest Semaglutide News and Research

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

12 Feb 2025

Insilico Medicine announces preclinical drug discovery benchmarks from 2021 to 2024

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate nominations achieved by its platform from 2021 to 2024.

11 Feb 2025

Diabetes medications may help lower COPD flare-up risk, study finds

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical trials to confirm these findings.

11 Feb 2025

Vision loss risks in patients using popular GLP-1 medications raise concerns

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established. That is the conclusion of a retrospective study published online on Jan. 30 in JAMA Ophthalmology.

7 Feb 2025

Communication between body muscle and pituitary gland may play unexpected role in female fertility

A newly discovered line of communication between body muscle and the pituitary gland may play an unexpected role in female fertility, according to a new study.

6 Feb 2025

GLP-1 drug exenatide shows no benefit for Parkinson's in new study

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

4 Feb 2025

High discontinuation rates of GLP-1 agonists found among patients with obesity

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

4 Feb 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

Gut-derived sugars: A potential game-changer for weight management and diabetes

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA production, and improving glucose homeostasis. S. salivarius, a key EPS producer, shows potential for obesity and diabetes intervention.

30 Jan 2025

Revolutionizing diabetes care with innovative targets and therapeutic options

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options.

30 Jan 2025

Weekly diabetes injection could replace daily shots for lipodystrophy patients

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients with almost zero fat tissue, according to a study in The New England Journal of Medicine.

29 Jan 2025

GLP-1RA initiation linked to new thyroid cancer diagnoses

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor agonists.

28 Jan 2025

An Arm and a Leg: The ‘Shkreli Awards’ — for dysfunction and profiteering in health care

Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" in health care and "honors" the winners.

27 Jan 2025

Boosting BCL6 may counteract muscle loss from GLP-1 medications

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

23 Jan 2025

What causes behavioral side effects in popular weight loss drugs?

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

23 Jan 2025

Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

22 Jan 2025

GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been linked with behavioral side effects.

22 Jan 2025

Childhood obesity treatment reduces long-term health risks but not depression

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young adulthood.

21 Jan 2025

Benefits and risks of popular weight-loss drugs revealed

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

20 Jan 2025

Researchers create an atlas of health associations for GLP-1 receptor agonists

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

20 Jan 2025